WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke EVOX THERAPEUTICS wurde als Wortmarke am 15.12.2016 bei der Weltorganisation für geistiges Eigentum angemeldet.
| Markenform | Wortmarke |
| Aktenzeichen | 1348112 |
| Registernummer | UK00003168512 |
| Länder | 
|
| Basismarke |
Nr. UK00003168512,
16. September 2016
|
| Anmeldedatum | 15. Dezember 2016 |
| Ablaufdatum | 15. Dezember 2026 |
Markeninhaber
King Charles House,
Park End Street
GB
Park End Street
GB
Markenvertreter
80 Turnmill Street
London EC1M 5QU
GB
Waren und Dienstleistungen
05
Pharmaceuticals; pharmaceutical preparations and substances;
pharmaceutical preparations, namely, a drug delivery system
comprising genetically engineered or purified exosomes for
therapeutic use; pharmaceutical preparations, namely,
exosomes to deliver protein for genetic therapy; medicine;
medical preparations and articles; biological preparations
for medical purposes; biological preparations for the
treatment of cancer, diabetes, obesity, metabolic syndrome,
dementia, and other aging associated pathologies such as
mitochondrial disease, joint/ligament strain/tears, muscle
atrophy, muscular dystrophy; biological preparations
comprising exosome; biological preparations comprising a
therapeutic target protein-loaded exosome; biological
preparations comprising exosome for pharmaceutical purposes;
biological reagents for medical use; mixed biological
preparations for medical purposes; mixed biological
preparations for the prevention and treatment of infectious
diseases; diagnostic reagents used in the fields of
biological, genetic engineering and pharmaceutical research;
diagnostic reagents comprising exosome used in the fields of
biological, genetic engineering and pharmaceutical research;
pharmaceuticals, medicines, biologics, biotherapeutics,
biosimilars and therapeutics, namely, EV-based nucleic acid
therapeutics for the prevention and treatment of infections
or disease; diagnostic kits comprised of medical diagnostic
reagents and assays for testing of bodily fluids for use in
disease detection; diagnostic kits comprised of medical
diagnostic reagents and assays for testing of exosomes for
use in disease detection; diagnostic kits comprised of
medical diagnostic reagents and assays that test for the
presence of cancer, diabetes, obesity, metabolic syndrome,
dementia, and other aging associated pathologies such as
mitochondrial disease, joint/ligament strain/tears, muscle
atrophy, muscular dystrophy
42
Scientific, medical and pharmaceutical research and
development services; pharmaceutical drug development
services; research and development of pharmaceutical
preparations; research and analysis services; biological
research; clinical research; providing medical and
scientific research information in the field of filtration
of exosomes from blood; scientific investigations for
medical purposes; scientific laboratory services; medical
research laboratory services; laboratory research services
relating to pharmaceuticals; research and development in the
field of biotherapeutics for the treatment of infectious
diseases and metabolic disorders; consulting services in the
fields of biotechnology, pharmaceutical research and
development and genetic science
44
Medical services; medical and pharmaceutical consultancy;
medical services relating to the diagnosis and treatment of
persons; laboratory analysis service relating to the
diagnosis and treatment of persons; medical analysis and
examinations; medical treatment services; medical screening;
medical monitoring, testing, inspection and analysis
services relating to the diagnosis and treatment of viral
and bacterial based infections and diseases; medical
monitoring, testing, inspection and analysis services
relating to the diagnosis and treatment of cancer, diabetes,
obesity, metabolic syndrome, dementia, and other aging
associated pathologies such as mitochondrial disease,
joint/ligament strain/tears, muscle atrophy, muscular
dystrophy
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 05. April 2023 | 2023/14 Gaz | US | Ablehnung |
| 01. Dezember 2022 | 2022/50 Gaz | Korrektur | |
| 16. Dezember 2020 | 2020/52 Gaz | CN | Ablehnung |
| 03. August 2020 | 2020/32 Gaz | Korrektur | |
| 18. Mai 2020 | 2020/21 Gaz | Löschung | |
| 15. März 2018 | 2018/16 Gaz | JP | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 26. Oktober 2017 | 2017/43 Gaz | JP | Ablehnung |
| 18. Oktober 2017 | 2017/44 Gaz | EM | Ablehnung |
| 21. September 2017 | 2017/38 Gaz | AU | Ablehnung |
| 20. Juni 2017 | 2017/25 Gaz | US | Ablehnung |
| 15. Dezember 2016 | 2017/20 Gaz | GB | Eintragung |
ID: 141348112